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olus in the Prevention of Ischemic
omplications During High-Risk Coronary Angioplasty
he ADVANCE Trial
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OBJECTIVES We sought to determine the safety and efficacy of high-dose bolus (HDB) tirofiban in
high-risk patients undergoing percutaneous coronary intervention (PCI).
BACKGROUND The use of HDB tirofiban in the catheterization laboratory is controversial. In particular, in
patients with acute coronary syndromes undergoing PCI, there is no evidence that tirofiban
administered in the catheterization laboratory is superior to heparin alone. This finding
probably reflects the suboptimal platelet inhibition when tirofiban is employed at RESTORE
(Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis) regimen.
METHODS A total of 202 patients (mean age 69  8 years; 137 males [68%]) undergoing high-risk PCI,
pretreated with thienopyridines, were consecutively randomized to HDB tirofiban (25
g/kg/3 min, and infusion of 0.15 g/kg/min for 24 to 48 h) or placebo immediately before
the procedure and then followed for a median time of 185 days (range 45 to 324 days) for the
occurrence of the primary composite end point of death, myocardial infarction, target vessel
revascularization (TVR), and bailout use of glycoprotein (GP) IIb/IIIa inhibitors.
RESULTS The cumulative incidence of the primary end point was 35% and 20% in placebo and HDB
tirofiban groups, respectively (hazard ratio 0.51, 95% confidence interval 0.29 to 0.88; p 
0.01). This difference was mainly due to the reduction of myocardial infarction and bailout
use of GP IIb/IIIa inhibitors, with no significant effect on TVR or death. The safety profile
did not differ between tirofiban and placebo.
CONCLUSIONS The use of tirofiban, when administered at HDB, is safe and significantly reduces the
incidence of ischemic/thrombotic complications during high-risk PCI. (J Am Coll Cardiol
2004;44:14–9) © 2004 by the American College of Cardiology Foundationn
r
d
p
u
e
r
p
t
p
w
P
a
A
t
P
i
Reveral randomized, controlled trials have assessed the
fficacy of the upstream administration of tirofiban (Platelet
eceptor Inhibition for ischemic Syndrome Management in
atients Limited to very Unstable Signs and symptoms
PRISM-PLUS] regimen) in patients with non–ST-
egment elevation acute coronary syndromes (ACS) (1,2).
ccordingly, this has been endorsed as a class I indication in
he most recent American and European guidelines (3,4).
t the same time, the use of tirofiban as an adjunctive
edication in the catheterization laboratory (Randomized
fficacy Study of Tirofiban for Outcomes and Restenosis
RESTORE] regimen) for the prevention of ischemic
omplications during percutaneous coronary intervention
PCI) gave controversial results.
In the RESTORE trial, the use of tirofiban led to a
From the *Department of Cardiology, University of Ferrara, Ferrara; †Cardiovas-
ular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS),
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as supported by a grant from Cassa dei Risparmi di Ferrara, Italy.
Manuscript received January 28, 2004; revised manuscript received February 24,004, accepted March 2, 2004.onsignificant reduction of the primary end point with
espect to unfractioned heparin alone (5), and, when
irectly compared with abciximab in a broad group of
atients submitted to both urgent and elective PCI, the
se of tirofiban offered less protection from major isch-
mic events (6). The reasons for these results are cur-
ently speculative and possibly due to an inadequate early
latelet inhibition of tirofiban at RESTORE regimen in
he trials.
Platelet reactivity is pivotal in the pathogenesis of com-
lications after PCI (7), and the degree of platelet inhibition
ith the use of glycoprotein (GP) IIb/IIIa inhibitors during
CI is critical for the protection from ischemic events (8).
In the randomized comparison of platelet inhibition with
biciximab, tirofiban, and eptifibatide during PCI in the
CS (Comparison Of Measurements of Platelet aggrega-
ion with Aggrastat, Reopro, and Eptifibatide [COM-
ARE] trial), platelet aggregation 15 and 30 min after drug
nfusion was significantly less inhibited with the tirofiban-
ESTORE regimen compared with abciximab and eptifi-
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RISM-PLUS regimen (9).
Accordingly, the bolus of tirofiban regimen has been
evised and increased from 10 to 25 g/kg (HDB tirofiban)
10). From preliminary uncontrolled findings, this new
egimen appears safe (11), but data on its efficacy are still
canty.
To this end, the aim of the current study was to
etermine whether the administration of HDB tirofiban is
uperior to unfractioned heparin alone in patients undergo-
ng high-risk PCI.
ETHODS
atients. This was a single-center, double-blind, placebo-
ontrolled, randomized trial comparing HDB tirofiban with
lacebo in patients undergoing elective or urgent PCI with
linical or angiographic high-risk features. Our local ethics
ommittee on Human Research approved the protocol, and
ll participants gave their written, informed consent. From
arch 2002 to August 2003, 202 patients (of 578 screened)
ere consecutively enrolled on the basis of the following
nclusion criteria: 1) the presence of at least one coronary
arrowing 70% amenable to coronary stenting (except an
nprotected left main stenosis or bypass graft) and the
resence of diabetes mellitus; or 2) a planned multivessel
ntervention (stenting of 2 lesions of least 70% coronary
tenosis in different coronary vessels); or 3) the presence of
on–ST-segment elevation ACS. Exclusion criteria were
T-segment elevation myocardial infarction (MI), admin-
stration of any GP IIb/IIIa inhibitors during the previous
wo weeks, serum creatinine 2.5 mg/dl (221 mol/l),
ngoing bleeding or bleeding diathesis, previous stroke in
he last six months, major surgery within the previous six
eeks, and platelet count 100,000 per mm3.
andomization. Patients who met the eligibility criteria
ere randomly assigned (by the use of computer-based 1:1
andomization scheme) to tirofiban or placebo (0.9% NaCl
olution) by an independent study nurse. The study drug
olus was given at least 5 min before the lesion could be
rossed with the guide wire. Analyses of the data are based
n the intention-to-treat principle.
edications and procedures. As per the protocol, all
atients were pretreated with aspirin (160 to 325 mg orally)
nd thienopyridine (ticlopidine 500 mg as a loading dose
Abbreviations and Acronyms
ACS  acute coronary syndrome
ACT  activated clotting time
CK  creatine kinase
GP  glycoprotein
HDB  high-dose bolus
MI  myocardial infarction
PCI  percutaneous coronary intervention
TVR  target vessel revascularizationnd then 250 mg twice daily or clopidogrel 300 mg orally as mloading dose and then 75 mg/day at least 48 or 6 h before
he procedures, respectively). Any stent type approved by a
egulatory agency could be implanted. Tirofiban was given
s a bolus of 25 g/kg per 3 min, followed by an infusion of
.15 g/kg/min for 24 to 48 h. Heparin was adjusted as
ollows: patients assigned to tirofiban received 50 to 70
/kg heparin (maximum 7,000 U), with additional boluses
o achieve and maintain an activated clotting time (ACT) of
t least 200 s. Patients assigned to placebo received an initial
olus of 100 U/kg (maximum 10,000 U), with additional
oluses to achieve and maintain an ACT of at least 300 s.
he protocol advised to discontinue heparin after the
rocedure and remove the arterial sheath when the ACT
as 180 s, with an arteriotomy closure device or with
xternal compression for hemostasis. Investigators could
odify these guidelines at their discretion to meet the
edical needs on a patient-by-patient basis. Patients could
e discharged after completion of the study drug, but not
48 h after revascularization.
tudy end points. The primary end point was a composite
f death, nonfatal MI, urgent TVR, and thrombotic bailout
P IIb/IIIa inhibitor therapy within a median follow-up of
80 days after the index procedure. A new MI was defined
s the finding of levels of the MB isoform of creatine kinase
CK-MB) that were above at least three times the upper
imit of the normal range in at least one blood sample or by
he finding of abnormal Q-wave in two or more contiguous
eads. Plasma levels of CK, CK-MB, and troponin I were
easured in all patients at baseline, 6 and 18 h after the
rocedure, and when clinically needed. For patients with a
ecent MI who had an elevated CK-MB level before the
rocedure, a value of more than three times the upper limit
f normal and at least 50% above the last preprocedural
evels was required to meet the definition. Urgent vessel
evascularization included any coronary artery bypass graft
urgery or a second PCI of the original target vessel(s)
erformed on a nonelective basis for recurrent myocardial
schemia. Similarly, patients who received bailout GP IIb/
IIa inhibitor therapy were adjudicated as an end point if
reatment was given to manage a thrombotic complication,
efined as the development of a new filling defect or
aziness consistent with thrombosis, abrupt closure, or
he development of distal/2 mm side-branch macro-
mbolization (12). Once bailout treatment was underway,
tudy drug infusion or placebo was discontinued and
witched to an infusion of open-label abciximab. Bailout
P IIb/IIIa inhibitor use did not result in unblinding of
tudy drug assignment.
Secondary end points included each component of the
omposite end point, the effects of study drug on troponin
release after the procedure, and the effects of study
edication on prespecified subgroups, defined according to
he presence or absence of diabetes and ACS as the
ndication for PCI.
For an analysis of safety, the end points of major and
inor bleeding complications were defined according to the
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High-Dose Bolus Tirofiban in Coronary Angioplasty July 7, 2004:14–9riteria of the Thrombolysis In Myocardial Infarction
TIMI) trial (13).
tatistical analysis. A total of 199 patients were required
or the study to have 80% power to determine whether
DB tirofiban was superior to placebo, given a 30% rate of
vents at month 6 in the placebo group and an expected 40%
eduction in the tirofiban arm with an alpha error of 5%.
he one-tailed Peterson and George method (14), along
ith the formulas of Schoenfeld (15,16), was employed,
onsidering an accrual time of one year and a follow-up time
f six months.
Values are expressed as mean  SD. Comparisons
etween the two groups were performed with the Student t
est. The Fisher exact test was used for categorical variables.
he time to first occurrence for the composite end point is
isplayed with Kaplan-Meier survival curves. The log-rank
est has been used to compare survival in tirofiban and
lacebo groups. The Cox proportional hazards model has
een used to calculate adjusted hazard ratios based on the
ime to event. Probability was significant at a level of0.05.
tatistical analysis was performed using Statistica 6.1 Soft-
are (Statsoft Inc., Tulsa, Oklahoma).
ESULTS
he baseline characteristics of the patients are provided in
able 1. Among ACS patients, 45 (82%) in the treatment
able 1. Baseline Characteristics of the Patients
Characteristics
Placebo
(n  101)
HDB
Tirofiban
(n  101)
p
Value
ge (yrs) 68  7 69  9 NS
ale gender (%) 66 69 NS
eight (kg) 81.4 80.1 NS
iabetes (%) 45 53 NS
ypertension (%) 45 50 NS
moker (%) 21 19 NS
reatinine (mg/dl) 1.1  0.3 1.0  0.2 NS
V ejection fraction (%) 55 53 NS
edical history (%)
CABG 4 3 NS
PCI 38 32 NS
Myocardial infarction 45 52 NS
Heart failure 15 19 NS
Cerebrovascular accident 3 5 NS
ndications to PCI (%)
Acute coronary syndrome 55 56 NS
Stable angina 37 29 NS
Silent ischemia 7 12 NS
Myocardial viability 1 3 NS
edications (%)
Clopidogrel/ticlopidine 65/35 62/38 NS
Statin 87 91 NS
ACE inhibitor 65 71 NS
Beta-blocker 76 65 NS
ata are presented as the mean value  SD or percentage of patients.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass
rafting; HDB  high-dose bolus; LV  left ventricular; NS  not significant; PCI
percutaneous coronary intervention.nd 41 (76%) in the placebo arm presented with one orore high-risk features (4), with 41 patients (75%) in the
DB tirofiban and 39 (72%) in the placebo group showing
roponin I elevation at entry. Other common high-risk
eatures were ST-segment depression 0.5 mm in two or
ore electrocardiographic leads and the presence of diabe-
es, which were present in 28 (51%) and 16 (29%) patients
n the HDB tirofiban and 33 (61%) and 10 (19%) patients
n the placebo group, respectively. In the remaining 93
lective patients, 36 (39%) and 28 (30%) in the treatment
roup and 35 (38%) and 32 (34%) in the placebo group
resented with diabetes or received multivessel intervention,
espectively; the prevalences of type B2 and C coronary
esions were 33% and 12% in the treatment and 29% and
3% in the placebo arms, respectively.
All patients assigned to HDB tirofiban received the study
rug. Tirofiban was infused for a mean (SD) of 26.2 
.5 h. One patient in the tirofiban group and seven patients
n the placebo group underwent 12-h infusion of heparin
fter the procedure: the main reasons were distal macro-
mbolization, residual vessel dissection, and reduced TIMI
ow in a side branch. Procedural data are shown in Table 2.
In both groups, 98% of patients underwent stenting. The
ean heparin dose and mean maximum ACT were signif-
cantly higher in the placebo group.
linical outcome. The incidences of the primary end point
fter a median follow-up of 185 days (range 45 to 324) were
5% and 20% in the placebo and HDB tirofiban groups,
espectively (Fig. 1), resulting in a difference of 42% (hazard
atio 0.51, 95% confidence interval 0.29 to 0.88; p 0.01 by
he log-rank test). The difference in the incidence of events
etween the two groups emerged soon after the procedure
Fig. 1). The absolute difference was mainly the result of the
ifference in the incidence of MI (10.8% in the placebo
able 2. Procedural Data
Characteristics
Placebo
(n  101)
HDB
Tirofiban
(n  101)
p
Value
rimary target vessel (%)
LAD 42 39 NS
RCA 33 34 NS
LCA 25 27 NS
ultivessel intervention (%) 33 29 NS
ifurcations (%) 22 28 NS
elivery of at least 1 stent (%) 98 98 NS
1 Stent implanted (%) 39 33 NS
eference diameter (mm) 2.6  0.3 2.7  0.4 NS
eparin dose (U) 9,500 5,400 0.01
ctivated clotting time (s) 310 243 0.02
eparin after sheath removal (%) 7 0 0.05
CC/AHA lesion type (%)
A 13 10 NS
B1 32 30 NS
B2 38 41 NS
C 17 19 NS
ata are presented as the percentage of patients or mean value  SD.
ACC/AHA  American College of Cardiology/American Heart Association;
DB  high-dose bolus; LAD  left anterior descending coronary artery; LCA 
eft circumflex artery; RCA  right coronary artery.
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July 7, 2004:14–9 High-Dose Bolus Tirofiban in Coronary Angioplastyroup and 3.9% in the tirofiban group, p  0.052) and of a
ignificant difference in the incidence of MI and bailout GP
Ib/IIIa inhibitor administration (14.7% in the placebo
roup and 3.9% in the tirofiban group, p  0.02) (Table 3).
roponin I and CK-MB. At baseline, troponin I and
K-MB levels did not differ between the HDB tirofiban
roup compared with placebo (0.32  0.2 and 3.3  5.8
g/ml vs. 0.30  0.22 and 3.8  6.3 ng/ml, respectively),
lthough they peaked significantly higher after PCI in the
lacebo compared with HDB tirofiban group (5.7  8.3
nd 13.2  16.4 ng/ml vs. 1.6  1.1 and 5.3  2.3 ng/ml,
 0.001 and p  0.01, respectively). Troponin I levels
ere significantly higher after PCI in the placebo group also
fter the exclusion of patients who satisfied the criteria for
eriprocedural MI (0.05  0.02 vs. 0.07  0.03 ng/ml at
aseline and 0.3  0.1 vs. 1.1  2.0 ng/ml, p  0.001, in
he HDB tirofiban and placebo groups, respectively). At
ntry, patients with troponin I elevation beyond the upper
ormal limit did not differ between the two groups (as
iscussed subsequently). After PCI, troponin I was elevated
n 55 patients in the HDB tirofiban group versus 83 in the
lacebo group (p  0.04). Three patients in the placebo
igure 1. Kaplan-Meier survival analysis: plot of proportion of cumulative
urvival free from primary end point events in patients treated with
igh-dose bolus (HDB) tirofiban (solid line) and placebo (dotted line).
he difference in the incidence of events emerged soon after the procedure.
t month 6, the hazard ratio was 0.51 (95% confidence interval 0.29 to
.88, p  0.01 by the log-rank test).
Table 3. Clinical Outcome at Six Months
Clinical Events
Pl
(n
Primary end point (%)
Death/MI/TVR (%)
Death (%)
Myocardial infarction (%)
Target vessel revascularization (%)
Bailout GP IIb/IIIa inhibitor use (%)
MI/bailout GP IIb/IIIa inhibitor (%)
Death/MI/bailout GP IIb/IIIa inhibitor (%)CI  confidence interval; GP  glycoprotein; MI  myocardial iroup versus none in the HDB tirofiban group showed
ajor (5  normal) CK-MB elevation after PCI.
ubgroup analysis. The hazard risk of the primary end
oint in patients treated with tirofiban or placebo according
o the prespecified subgroups is reported in Figure 2. As
hown, a reduction in the incidence of the primary end
oint was consistent among patients with ACS or diabetes.
afety data. No major bleedings and no need for red cell
ransfusion occurred in the study population. Minor bleed-
ngs were four in the HDB tirofiban group (two gross
ematuria and two groin hematoma) and one in the placebo
roup (p  0.19). There was no severe thrombocytopenia.
ne patient in each group had mild thrombocytopenia.
ISCUSSION
he results of our study show that the administration of
DB tirofiban, when given immediately before PCI pro-
edures, is more effective than heparin alone in the preven-
ion of ischemic complications after high-risk coronary
ngioplasty. In particular, the comparison of survival curves
etween placebo and tirofiban groups indicates an early
enefit in the latter after PCI that remained almost un-
hanged at month 6, supporting the hypothesis that it is
ainly due to a periprocedural protection. We observed no
lear effect when death or TVR were separately analyzed.
ather, there was a borderline reduction in MI incidence
nd no need for bailout GP IIb/IIIa inhibitor administra-
ion to manage thrombotic complications in the tirofiban
)
Tirofiban
(n  101)
Hazard Ratio
(95% CI) p Value
20 0.51 (0.88–0.29) 0.01
20 0.57 (0.99–0.33) 0.048
2 1.7 (19–0.15) 0.6
4 0.34 (1.08–0.11) 0.052
14 0.64 (1.28–0.32) 0.29
0 0.15 (1.29–0.01) 0.08
4 0.23 (0.75–0.08) 0.01
6 0.34 (0.88–0.13) 0.03
igure 2. Subgroup analysis. Hazard risk of primary end point according to
he presence or absence of acute coronary syndrome as an indication to
ercutaneous coronary intervention or a history of diabetes. The horizontal
ines indicate the 95% confidence interval.acebo
 101
35
31
1
11
19
4
15
16nfarction; TVR  target vessel revascularization.
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High-Dose Bolus Tirofiban in Coronary Angioplasty July 7, 2004:14–9rm. On the whole, the use of HDB tirofiban led to a
ignificant reduction of the incidence of both primary end
oint and major adverse cardiac events (death/TVR/MI).
he effect of tirofiban in our study was on top of thienopy-
idine pretreatment, as, per protocol, all patients included in
oth arms received clopidogrel or ticlopidine at least 6 and
8 h before PCI, respectively (17,18).
Our study population is not representative of the entire
pectrum of patients undergoing PCI in our centre, because
e selected patients with clinical (ACS or history of
iabetes) or angiographic (multivessel interventions) high-
isk features. This explains the high incidence of cardiac
vents in the placebo group.
In the RESTORE trial, where only patients with ACS
ere included, the use of tirofiban led to a nonsignificant
eduction of the primary end point at 30 days, as compared
ith heparin alone (5). Similarly, in the Tirofiban And
eoPro Give similar Efficacy outcomes Trial (TARGET),
atients with stable coronary syndromes had similar or
etter outcomes with tirofiban versus abciximab, whereas
CS patients presented a clear opposite response (19).
ecently, the Troponin in Planned PTCA/Stent Implan-
ation With or Without Administration of the Glycopro-
ein IIb/IIIa Receptor Antagonist Tirofiban (TOPSTAR)
rial, which included 96 patients submitted to elective PCI,
howed a marked benefit of tirofiban compared with hepa-
in alone in terms of major adverse cardiac events and
K/troponin release (20). Because ACS patients display
pregulation of platelet IIb/IIIa receptors and higher plate-
et reactivity, as compared with stable patients, these previ-
us results are in keeping with the hypothesis that ACS
atients, who need the strongest antiplatelet activity, are
hose who are relatively less protected with tirofiban in the
ESTORE regimen.
We intentionally included in this trial both elective and
rgent PCI in order to assess the differential effect of HDB
irofiban in both groups of patients. Our results indicate that
t this revised regimen, tirofiban is apparently more effective
n ACS patients than in stable ones, indirectly confirming
he validity of the previous hypothesis.
In vitro and ex vivo studies have shown that diabetic
atients have increased platelet aggregability (20–23). In
articular, diabetes mellitus has been associated with a larger
ool of activated circulating platelets (24), a higher density
f GP IIb/IIIa receptors per platelet (24), and a greater
xpression of platelet P-selectin and thrombospondin (25).
n the present study, a history of diabetes mellitus was an
nclusion criterion among elective patients, so that 45% and
3% of patients in the placebo and tirofiban groups were
iabetic, respectively.
Our data show that diabetic patients have a relative higher
enefit from HDB tirofiban versus heparin alone, as compared
ith nondiabetic patients. This observation confirms the pre-
ious findings and reinforces the notion that diabetic patients,
rrespective of their clinical status, would probably benefit from
tailored drug regimen during PCI (26).In the current study, the safety profile of HDB tirofiban
as remarkable, as no major differences were observed in the
reated arm versus placebo. However, this could also reflect
he fact that our study was underpowered to detect small
ifferences between groups.
tudy limitations. We did not assess the effect of HDB
irofiban on the degree of platelet inhibition, because this
as the object of several previous studies (9–11). However,
his would have potentially provided additional insights into
he relationship between the degree of platelet inhibition
nd clinical outcome in our trial. Additional studies are
eeded to better understand the relative role of optimal
osing of the bolus and infusion time on clinical outcome.
onclusions. Our investigation on the use of HDB tiro-
ban indicates, for the first time, that the study drug, at the
mployed regimen, is superior to heparin alone in high-risk
atients undergoing PCI. The treatment effect appears to be
ainly due to periprocedural protection from ischemic/
hrombotic complications, whereas no significant effect was
een on TVR. At present, the effect of study drug on
ortality is unclear and out of the scope of our phase II
nvestigation. At the subgroup analysis, the treatment effect
ppears consistent both in patients presenting with ACS
nd in those with diabetes. Our current findings, based on
limited and selected sample size, should be viewed as
reliminary, thus giving input for further research in this
eld.
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